| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | carboplatin:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.39 | 0.02 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.099 | 0.03 |